While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Seven hundred and fifty-one patients were assigned to the 70.2 Gy group and 748 were assigned to the 79.2 Gy group. The median follow-up was 8.4 years.
A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
While patients who received docetaxel had a significant decrease in FACT-P-reported QoL between baseline and 3 months, no difference was noted between baseline and 12 months.
Recommendations about population-wide PSA screening are mixed, with some studies suggesting that the potential benefits of early diagnosis are outweighed by overtreatment.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
A study could not determine whether one liquid biopsy panel is more accurate than another overall.
Apalutamide is also the first agent to be approved for meeting the primary endpoint of metastasis-free survival.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.
In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.
It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.
Epidemiologic data of flaxseed dietary intake and high enterolactone serum concentrations suggest that flaxseed consumption may reduce the risk of breast cancer.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.
It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.
A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.
AS is recommended for men with low-risk PCa; this option can mitigate treatment-related reduction in quality of life.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Previous studies demonstrated that patients with metastatic hormone-sensitive prostate cancer treated with docetaxel have prolonged overall survival.
Hypofractionated radiotherapy's role in postoperative settings remains unclear and awaits outcomes from ongoing studies.
Researchers accessed the National Prostate Cancer Register of Sweden to evaluate the treatment strategies and outcomes for 74,643 patients with Pca.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
Abiraterone acetate, prednisone, and ADT improve outcomes in the metastatic castration-naive setting, though whether this combination improves PROs and HRQoL was previously unknown.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
Researchers assessed CTC and PSA response endpoints in 6081 patients enrolled in 1 of 5 randomized phase 3 studies.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy